Questions That Remain Regarding Combination, Sequencing With PARP Inhibitors

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

FDA Issues CRL to BLA for [Vic-] Trastuzumab Duocarmazine in HER2+ mBC

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Comparing Elacestrant Vs Fulvestrant for ESR1-Mutated Breast Cancer

NSCLC Treatment Cost Significantly Increases Over 7-Year Span

Luspatercept Increases Probability of Transfusion Independence in Lower-Risk MDS

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

FDA Issues CRL to BLA for [Vic-] Trastuzumab Duocarmazine in HER2+ mBC

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Comparing Elacestrant Vs Fulvestrant for ESR1-Mutated Breast Cancer

NSCLC Treatment Cost Significantly Increases Over 7-Year Span

Luspatercept Increases Probability of Transfusion Independence in Lower-Risk MDS

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

FDA Issues CRL to BLA for [Vic-] Trastuzumab Duocarmazine in HER2+ mBC

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Comparing Elacestrant Vs Fulvestrant for ESR1-Mutated Breast Cancer

NSCLC Treatment Cost Significantly Increases Over 7-Year Span

Luspatercept Increases Probability of Transfusion Independence in Lower-Risk MDS

Related Content

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

FDA Issues CRL to BLA for [Vic-] Trastuzumab Duocarmazine in HER2+ mBC

Podcast

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Listen

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

The FDA has requested additional information regarding vic-trastuzumab duocarmazine to further evaluate the agent for patients with HER2-positive metastatic breast cancer.

Comparing Elacestrant Vs Fulvestrant for ESR1-Mutated Breast Cancer

Podcast

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Listen

NSCLC Treatment Cost Significantly Increases Over 7-Year Span

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants what they see as the role of elacestrant for patients with ER+, HER2-negative breast cancer. This is the second of 2 articles based on this event.